Published in final edited form as:

Biochemistry. 2006 May 23; 45(20): 6392–6406.

Effects of Biological Oxidants on the Catalytic Activity and Structure of Group VIA Phospholipase A₂[†]

Haowei Song, Shunzhong Bao, Sasanka Ramanadham, and John Turk^{*}

Medicine Department Mass Spectrometry Facility, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110

Abstract

Group VIA phospholipase A₂ (iPLA₂ β) is expressed in phagocytes, vascular cells, pancreatic islet β -cells, neurons, and other cells and plays roles in transcriptional regulation, cell proliferation, apoptosis, secretion, and other events. A bromoenol lactone (BEL) suicide substrate used to study iPLA₂ β functions inactivates iPLA₂ β by alkylating Cys thiols. Because thiol redox reactions are important in signaling and some cells that express iPLA₂ β produce biological oxidants, iPLA₂ β might be subject to redox regulation. We report that biological concentrations of H₂O₂, NO, and HOCl inactivate iPLA₂ β , and this can be partially reversed by dithiothreitol (DTT). Oxidant-treated iPLA₂ β modifications were studied by LC–MS/MS analyses of tryptic digests and included DTT-reversible events, e.g., formation of disulfide bonds and sulfenic acids, and others not so reversed, e.g., formation of sulfonic acids, Trp oxides, and Met sulfoxides. W⁴⁶⁰ oxidation could cause irreversible inactivation because it is near the lipase consensus sequence (⁴⁶³GTSTG⁴⁶⁷), and site-directed mutagenesis of W⁴⁶⁰ yields active mutant enzymes that exhibit no DTT-irreversible oxidative inactivation. Cys651-sulfenic acid formation could be one DTT-reversible inactivation event because Cys651 modification correlates closely with activity loss and its mutagenesis reduces sensitivity to inhibition. Intermolecular disulfide bond formation might also cause reversible inactivation because oxidant-treated iPLA₂ β contains DTT-reducible oligomers, and oligomerization occurs with time- and temperature-dependent iPLA₂ β inactivation that is attenuated by DTT or ATP. Subjecting insulinoma cells to oxidative stress induces iPLA₂ β oligomerization, loss of activity, and subcellular redistribution and reduces the rate of release of arachidonate from phospholipids. These findings raise the possibility that redox reactions affect iPLA₂ β functions.

Phospholipase A₂ (PLA₂)¹ enzymes catalyze hydrolysis of *sn*-2 fatty acid substituents from glycerophospholipid substrates to yield a free fatty acid, e.g., arachidonic acid, and a 2-lysophospholipid that have intrinsic mediator activities and are precursors of prostaglandins, thromboxanes, leukotrienes, and platelet activating factor (PAF) (1-5). Mammalian PLA₂s include the PAF-acetylhydrolase family and low-molecular weight secretory PLA₂ (sPLA₂) enzymes that require millimolar Ca²⁺ concentrations for catalysis (3). Of group IV cytosolic PLA₂ (cPLA₂) family members (3), cPLA₂R prefers substrates with *sn*-2 arachidonoyl residues, associates with its substrates in membranes when the cytosolic Ca²⁺ concentration

[†]This work was supported by U.S. Public Health Service Grants R37-DK34388, R01-69455, P01-HL57278, P41-RR00954, P60-DK20579, and P30-DK56341.

^{*}To whom correspondence should be addressed: Washington University School of Medicine, Campus Box 8127, 660 S. Euclid Ave., St. Louis, MO 63110. Telephone: (314) 362-8190. Fax: (314) 362-7451. E-mail: jturk@wustl.edu.

¹Abbreviations: BEL, bromoenol lactone suicide substrate; BSA, bovine serum albumin; CAD, collisionally activated dissociation; DTT, dithiothreitol; ECL, enhanced chemiluminescence; ESI, electrospray ionization; HBSS, Hank's balanced salt solution; HPLC, high-performance liquid chromatography; iPLA₂ β , group VIA phospholipase A₂; IMAC, immobilized metal affinity chromatography; iNOS, inducible nitric oxide synthase; KRB, Krebs-Ringer bicarbonate buffer; LC, liquid chromatography; MEM, minimal essential medium; MPO, myeloperoxidase; MS, mass spectrometry; MS/MS, tandem mass spectrometry; NOS, nitric oxide synthase; PAGE, polyacrylamide gel electrophoresis; PLA₂, phospholipase A₂; Q-TOF, quadrupole time-of-flight; RT, reverse transcriptase; SD, standard deviation; SDS, sodium dodecyl sulfate.

risers, and is also regulated by phosphorylation (6). Several other cPLA₂ family members arise from separate genes (7-10).

Group VI PLA₂ (iPLA₂) enzymes (11-14) do not require Ca²⁺ for catalysis and are inhibited by a bromoenol lactone (BEL) suicide substrate that does not inhibit sPLA₂ or cPLA₂ at similar concentrations (15-18). Group VIA PLA₂ (iPLA₂β) resides in the cytoplasm of resting cells, but group VIB PLA₂ (iPLA₂γ) contains a peroxisomal targeting sequence and is membrane-associated (19-22). These enzymes belong to a larger class of serine lipases that are encoded by multiple genes (23,24). The iPLA₂β enzymes cloned from various species are 84–88 kDa proteins that contain a GX SXG lipase consensus sequence and eight stretches of a repetitive motif homologous to that in the protein-binding domain of ankyrin (11-13). No crystal structures of group VI PLA₂ family members have yet been determined.

Many potential biological functions are proposed for iPLA₂β (25-39), and the facts that multiple splice variants are differentially expressed among cells and form heterooligomers with distinct properties suggest that iPLA₂β gene products might have multiple functions depending on cellular context (27,28). Among the roles proposed for iPLA₂β are participation in phospholipid remodeling (25,26), signaling in secretion (29-31), apoptosis (32,33), vasomotor regulation (34,35), transcriptional regulation (36,37), eicosanoid generation (38,39), and cell proliferation (40-44).

Many cells express multiple distinct PLA₂ enzymes (13,17,18,45), and attempts to determine their individual functions have in large part relied on pharmacologic inhibitors that discriminate among PLA₂s. The mechanism-based iPLA₂ inhibitor BEL and its enantiomers (15,16,34) inhibit iPLA₂ at concentrations lower than those required to inhibit sPLA₂ or cPLA₂ enzymes (14-18), and this has been widely exploited in discerning potential biological roles for iPLA₂ (25-44). BEL affects more than one target (19,23,24,46,47), however, and it was first developed as an inhibitor of serine proteases, e.g., chymotrypsin (48,49). BEL is a substrate for chymotrypsin (48,49) and iPLA₂β (15,16), and its inhibitory effects require its hydrolysis by and result in covalent modifications of those enzymes (15,16,48,49). We recently demonstrated that BEL inhibits iPLA₂β by a mechanism that involves its hydrolysis to a diffusible bromomethyl ketoacid that alkylates cysteine thiols in the enzyme (50). This raises the possibility that iPLA₂β might be subject to redox regulation.

Factors that affect the oxidation state of cysteine thiols play important signaling roles in regulating transcription, the actions of growth factors and hormones, ion channel function, and other processes (51-54). Growth factors and insulin activate NADPH oxidases in some target cells to cause production of superoxide anion, which dismutates to H₂O₂, and H₂O₂ oxidizes cysteine thiols in the active sites of protein tyrosine phosphatases and lipid phosphatases to inactivate these enzymes (55). The iPLA₂β inhibitor BEL also inactivates some lipid phosphatases (46,47). Inactivation of protein tyrosine phosphatases by H₂O₂ amplifies the effect of growth factor receptor tyrosine kinases to induce tyrosine phosphorylation, and this appears to be required for optimal growth factor signaling because overexpression of peroxiredoxins that catalyze reduction of H₂O₂ attenuates growth factor action (56-58).

While a role for reactive oxygen and nitrogen intermediates in inflicting cellular injury and in killing pathogenic micro-organisms and tumor cells has long been recognized, many of these molecules also have signaling functions such as those described above for H₂O₂ that involve covalent modification of their targets (59). NO is another example of such a molecule (59). At the high concentrations produced by inducible NO synthase (iNOS), NO has microbicidal and tumoricidal actions, and at low concentrations produced by constitutive NOS isoforms, it plays signaling roles that often involve covalent modification of thiols (59). Hypochlorous acid (HOCl) is another biological oxidant produced from H₂O₂ and Cl⁻ by the enzyme

myeloperoxidase (MPO), and it participates in microbial killing by phagocytic cells (60-63). HOCl might also have signaling functions that involve thiol modification (64-70).

At pH 7.4, HOCl and OCI^- exist in an approximately equimolar ratio, and HOCl readily traverses cell membranes to interact with intracellular targets that include glutathione and thiol enzymes, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (63-66). This can activate signaling cascades, such as MAP kinase pathways and the tumor suppressor p53 (67-69). In addition, MPO expression in human brain neurons and in cultured neuronal cell lines has been demonstrated, and this raises the possibility that HOCl might play a signaling role in neurons analogous to that of NO produced by neuronal NO synthase (70). Neurons and insulin-secreting β -cells exhibit many biochemical similarities not shared by other cells (71, 72), and we find that cultured β -cells also express MPO (unpublished observations).

The influence of biological oxidants on iPLA $_2\beta$ is of interest because generation of superoxide and H_2O_2 from mitochondrial substrate overload and from tissue NADPH oxidases is thought to play a critical role in diabetic complications, including the progressive decline of β -cell function caused by hyperglycemia (73-77). iPLA $_2\beta$ is strongly expressed in β -cells and participates in insulin secretion and in β -cell proliferation and apoptosis (30,31,33,41), and effects of biological oxidants such as H_2O_2 on its activity might affect these processes. β -Cells stimulated with cytokines also produce NO via iNOS (78,79), and iPLA $_2\beta$ is required for iNOS induction in virally infected macrophages (37), suggesting that effects of NO on iPLA $_2\beta$ could be biologically significant. Phagocyte-derived HOCl is also believed to exert atherogenic effects on vascular endothelium (68,77), and iPLA $_2\beta$ is expressed in phagocytes (37), endothelium (80), and vascular myocytes (43). Both iPLA $_2\beta$ (81,82) and MPO (70) are also strongly expressed in brain, and effects of HOCl on iPLA $_2\beta$ could thus also be important.

We have therefore examined effects of the biological oxidants H_2O_2 , NO, and HOCl on the activity of purified, recombinant iPLA $_2\beta$ and have characterized oxidant-induced covalent modifications by digesting oxidant-treated iPLA $_2\beta$ with proteases and then analyzing peptides in the digest by LC-ESI-MS/MS.

EXPERIMENTAL PROCEDURES

Materials

Spodoptera frugiperda (Sf9) cells and culture medium were purchased from Invitrogen (Carlsbad, CA). TALON metal affinity resin was from Clontech (Palo Alto, CA). [5,6,8,9,11,12,14,15- ^3H]Arachidonic acid (217 Ci/ mmol), enhanced chemiluminescence (ECL) reagents, and 1-palmitoyl-2-[^{14}C]linoleoyl-*sn*-glycero-3-phosphocholine (16: 0/[^{14}C] 18:2-GPC) were from Amersham Biosciences (Piscataway, NJ). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) supplies and Coomassie Brilliant Blue stain were from Bio-Rad (Richmond, CA). Polyclonal antibodies to iPLA $_2\beta$ were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Gentamicin and INS-1 cell culture media were obtained from the Washington University Tissue Culture Support Center. The NO donor compound diethylamine NONQate and other chemicals were purchased from Sigma Chemical (St. Louis, MO). Solvents were purchased from Fisher Chemical (St. Louis, MO). PepMap HPLC columns and precolumns were obtained from LC-Packings (San Francisco, CA).

Oxidation Reactions

Stock solutions of H_2O_2 , HOCl, and the NO donor compound diethylamine NONQate were prepared and calibrated as described previously (83). Reactions were performed at 37 °C in buffer [50 mM Na_2HPO_4 and 20 mM imidazole (pH 7.8)] containing 0.2 $\mu\text{g}/\mu\text{L}$ iPLA $_2\beta$ with

various concentrations of oxidant for various intervals and terminated by adding a 10-fold molar excess of L-methionine.

Cloning, Expression, and Purification of Native and His-Tagged iPLA₂β Proteins

Sf9 cells were cultured as described previously (84). For protein expression, cDNA encoding iPLA₂β with a polyhistidine tag sequence at the C- or N-terminus (84) was cloned into the EcoRI–SalI site of pFastBac1 baculovirus shuttle vector (Invitrogen). Sf9 cell suspensions were infected with recombinant baculovirus, collected by centrifugation, and disrupted by sonication. His-tagged proteins were purified with a TALON metal affinity column, as described previously (84). Aliquots of protein solutions were analyzed by SDS–PAGE. Proteins were visualized by Coomassie staining or by being transferred to nylon membranes and immunoblotting, as described previously (84).

Assay of iPLA₂β Enzymatic Activity

Ca²⁺-independent PLA₂ enzymatic activity was assayed after ethanolic injection of substrate 1-palmitoyl-2-[¹⁴C]linoleoyl-*sn*-glycero-3-phosphocholine into assay buffer [40 mM Tris (pH 7.5) and 5 mM EGTA] by monitoring release of [¹⁴C]linoleate, as described previously (85).

Quantitation of Free Thiols

The amount of free thiol was measured with a thiol and sulfide quantitation kit from Molecular Probes (Eugene, OR) according to the manufacturer's instructions. In this spectrophotometric assay, thiols reduce an inactive disulfide derivative of papain (papain-SSCH₃) and release the active enzyme (papain-SH). Activated papain catalyzes hydrolysis of the chromogenic substrate, *N*-benzoyl-L-arginine-*p*-nitroanilide (L-BAPNA), resulting in an amplified spectrophotometric signal proportional to the amount of thiol. Enzyme activity is determined by measuring the absorbance at 410 nm of the *p*-nitroaniline chromophore released from L-BAPNA on a Titertek Multiskan MCC/340 microplate reader (ICN Biomedicals, Aurora, OH). Thiol concentrations in the samples are determined from measured absorbances by interpolation from a standard curve prepared with 0.1 mM L-Cys (50).

LC–ESI-MS/MS Analyses

As previously described (51), samples (0.2 μL) were injected into a Micromass (Manchester, U.K.) CapLC liquid chromatography system and concentrated on a PepMap C18 precolumn (300 μm × 5 mm). The precolumn was then washed (3 min, 0.1% formic acid, flow rate of 30 μL/min), and the sample was eluted onto an analytical C18 column (150 mm × 17 μm) and analyzed with a solvent gradient from solution A (3% acetonitrile) to solution B (95% acetonitrile) containing 0.1% formic acid over 50 min at a flow rate reduced from 5 μL/min to 200 nL/min by stream splitting. LC eluant was introduced into the nanoflow source of a Micromass Q-TOF Micro mass spectrometer. The source temperature was 80 °C, and the cone gas flow rate was 50 L/h. A voltage of 3.2 kV was applied to the nanoflow probe tip, and data were acquired in positive ion mode. Survey scans were integrated over 1 s, and MS/MS scans were integrated over 3 s. Switching from survey to MS/MS scan mode was performed in a data-dependent manner. The maximum MS/MS-to-survey scan ratio was 3. The collision energy was 28 eV. Data were processed with Masslynx version 3.5. Multipoint calibration was performed using selected fragment ions produced by CAD of Glu-fibrino-peptide B. MS/MS spectra were processed by Masslynx software to produce a peak list file, as described previously (84).

Site-Directed Mutagenesis of W⁴⁶⁰ to T⁴⁶⁰ or Y⁴⁶⁰ To Yield His-Tagged iPLA₂β Mutant Proteins

A 2.2 kb rat iPLA₂β cDNA was subcloned into the vector pBluescript II SK (Stratagene) and used for mutagenesis. Substitution of Thr460 or Tyr460 for Trp460 was performed with the QuickChange mutagenesis kit (Stratagene, La Jolla, CA), as described previously (50). The sequence of the forward primer was 5'-CCAAGGACCTCTTCGACACCGTGGCAGGAACCAGCACAG-3' and 5'-CCAAGGACCTCTTCGACTATGTGGCAGGAACCAGCACAG-3'. The fidelity of the construct was confirmed by sequencing, and the mutant cDNA was subcloned into the pFast-Bac1 vector, which was used to prepare recombinant baculovirus containing the mutant construct as an insert. His-tagged iPLA₂β^{T460} or iPLA₂β^{Y460} mutant protein was expressed in Sf9 cells and purified by immobilized metal affinity chromatography (IMAC), as described above.

Immunoblotting Analyses of iPLA₂β Protein

Protein in iPLA₂β preparations purified by IMAC after expression in an Sf9 cell-baculovirus system or proteins from INS-1 insulinoma cells that overexpress iPLA₂β were analyzed by 8% SDS-PAGE, transferred onto Immobilon-P PVDF membranes, and processed for immunoblotting analyses. iPLA₂β immunoreactive protein bands were visualized by enhanced chemiluminescence (ECL), as described previously (86).

Preparation of a Construct for Expressing iPLA₂β as a Fusion Protein with EGFP and Selection of Stably Transfected Clones

Full-length iPLA₂β cDNA was amplified by PCR using the following primer set: sense, 5'-AGCTTCGAATTCATGCAGTTCTTTGGACGC-3'; and antisense, 5'-TTCGATATCGGGAGATAGCAGCAGCTGG-3'. The amplified full-length iPLA₂β from the pMSCV-neo-iPLA₂β constructs were then subcloned into the pEGFP-N2 vector (Clontech) after the immediate-early promoter of cytomegalovirus major and before the EGFP coding sequences in the same code-reading frame as EGFP, as described previously (87). The EGFP-N2 control vector and the construct encoding iPLA₂β-EGFP (FPN2) fusion protein were transfected into INS-1 cells with a Gene PORTER transfection system according to the manufacturer's instructions (Gene Therapy Systems, San Diego, CA). Stably transfected clones were selected using G418 (0.4 mg/mL). Stably transfected cells obtained with the EGFP-N2 control vector and FPN2 construct are designed as N2 cells and FPN2 cells, respectively.

Fluorescence Microscopic Analyses of the Subcellular Distribution of EGFP-Tagged iPLA₂β in INS-1 Insulinoma Cells

The subcellular distribution of iPLA₂β protein was visualized in INS-1 cells that expressed EGFP-tagged iPLA₂β constructs by cytofluorescence analyses after the medium was removed and the cells were washed with PBS. Fluorescence microscopy was performed at an excitation wavelength of 550 nm and an emission wavelength of 570 nm, as previously described (87).

[³H]Arachidonic Acid Release Measurements

INS-1 insulinoma cells (5 × 10⁵ cells/well) were prelabeled for 20 h with [³H]arachidonic acid at a final concentration of 0.5 μCi/mL (5 nM) and incubated (1 h) in serum-free medium. Cells were then washed thrice with glucose-free RPMI-1640 medium to remove unincorporated radiolabel. Cell viability exceeded 98% by trypan blue exclusion. Labeled cells were incubated in RPMI-1640 medium containing 0.5% BSA at 37 °C and treated with various concentrations of diamide or vehicle for various intervals, as specified in the legend of Figure 11. Supernatants and cells were separated by centrifugation (500g for 5 min) and assayed for ³H content by liquid scintillation spectrometry, as described previously (86).

RESULTS

Effects of Biological Oxidants on iPLA₂ β Catalytic Activity and Cysteine Content

Affinity-purified, recombinant, His-tagged iPLA₂ β was treated with H₂O₂ at varied concentrations within the range that can be produced by cells (88,89). An H₂O₂-dependent loss of iPLA₂ β activity occurred, with ~50 and ~70% inhibition achieved at 50 and 70 μ M H₂O₂, respectively, and loss of activity correlated closely with loss of free thiol groups (Figure 1A). This suggests that oxidation of cysteine thiols is involved in inactivation of iPLA₂ β by H₂O₂, and activity could be restored completely by incubating the enzyme with dithiothreitol (DTT) after treatment with H₂O₂. This suggests that reversible oxidation events, such as formation of disulfide bonds or sulfenic acids (52,55), are responsible for H₂O₂-induced inactivation of iPLA₂ β .

Exposure of iPLA₂ β to NO by including various concentrations of the NO donor compound diethylamine NONQate in the incubation medium also resulted in a concentration-dependent loss of activity with ~50% inhibition achieved at a concentration of 100 μ M (Figure 1B). There was also a corresponding concentration-dependent loss of free thiol groups, but in contrast to the case for H₂O₂-treated iPLA₂ β , activity was incompletely restored (to 71% of the pretreatment level) by incubation with DTT after treatment with the NO donor. This indicates that NO caused some reversible oxidation or nitrosation event(s), perhaps including formation of sulfenic acids and disulfide bonds via Cys-S-NO intermediates (52), and also some events that were less readily reversible or irreversible, such as formation of sulfinic or sulfonic acids or other stable adducts (52,55).

Incubation of iPLA₂ β with HOCl also resulted in a concentration-dependent loss of activity, with 50 and 90% inhibition achieved at ~30 and ~100 μ M HOCl, respectively (Figure 1C), which are concentrations within the ranges observed to affect intracellular processes in intact cells without cell lysis (62,63,65,69). This was again associated with a corresponding loss of free thiols, and incubating HOCl-treated iPLA₂ β with DTT partially restored catalytic activity. Approximately one-third of the lost activity was not restored by DTT, and this presumably reflects formation of stable adducts that cannot be reduced by DTT, such as sulfinic or sulfonic acids, sulfenamides, oxidation products of methionine or tryptophan, or others (63,66,83, 90-92).

Identification of Stable Covalent Modifications of iPLA₂ β Caused by Biological Oxidants with LC-MS/MS Analyses

Tryptic digests of native and oxidant-treated iPLA₂ β were analyzed by LC-MS/MS to identify covalent modifications. Through a combination of search algorithms and direct data inspection, more than 73% sequence coverage was achieved for HOCl-treated iPLA₂ β . Figure 2 displays the complete amino acid sequence of iPLA₂ β , and only the underlined regions of sequence were not included in peptides identified by LC-MS/MS analyses of tryptic digests of the oxidant-treated enzyme. Figure 2 also identifies sites where oxidation products of methionine (MO), tryptophan (WO), or cysteine residues were observed.

Cysteine Oxidation

In the case of cysteine, both sulfenic (CO) and sulfonic (CO₃) acid derivatives were observed. Cysteine residues modified in HOCl-treated iPLA₂ β included Cys332, Cys559, and Cys651. Cys332 and Cys651 were oxidized to sulfenic acids, and the peptides that contained them exhibited an increase in mass of 16 Da compared to the mass of the tryptic peptides expected from the native iPLA₂ β sequence without modified amino acids, consistent with incorporation of one additional oxygen atom. Cys559 was oxidized to a sulfonic acid, and the peptide that

contained it exhibited an increase in mass of 48 Da compared to the mass of the expected native tryptic peptide, consistent with incorporation of three additional oxygen atoms.

Figure 3 is the singly charged MS/MS spectrum produced by deconvolution of the spectrum obtained from CAD of the $[M + 3H]^{3+}$ ion (m/z 834.39) of the tryptic peptide $^{644}\text{SPQVPVT}(\text{CO})\text{VDVFRPSNP}(\text{WO})\text{ELAK}^{665}$. The mass of the parent peptide is thus 2500.17, and the mass expected for the corresponding tryptic peptide from the native iPLA $_2\beta$ sequence is 2468.17. The difference between the observed and expected masses is thus 32, reflecting incorporation of two additional oxygen atoms. Singly charged fragment ions y^{14} (m/z 1674.01) and y^{15} (m/z 1792.87) identify Cys651 as the site of incorporation of one oxygen atom because the 119 unit difference between those ions exceeds the Cys residue mass by 16 units.

Tryptophan Oxidation

The observed m/z value of 1674.01 for the y^{14} fragment ion in Figure 3 is 16 units greater than the expected m/z value of 1657.9 for the y^{14} ion of the tryptic peptide from the native iPLA $_2\beta$ sequence, suggesting that an amino acid within the native sequence $^{652}\text{VDVFRPSNPWELAK}^{665}$ of iPLA $_2\beta$ had also been oxidized. The observed m/z value of 460.27 for the y^4 fragment ion corresponds to that expected for the tryptic peptide from the native iPLA $_2\beta$ sequence, and this indicates that the modified amino acid is contained in the sequence $^{652}\text{VDVFRPSNPW}^{661}$. An internal fragment ion at m/z 1234.83 represents the sequence $(y^{16})\text{VT}(\text{CO})\text{VDVFRPSN}(y^6)$, which indicates that the other oxidized amino acid in the $^{644}\text{S}-\text{K}^{665}$ parent peptide is contained within the $^{660}\text{PW}^{661}$ sequence. Because the cyclic proline side chain is much less susceptible to chemical oxidation than the tryptophan aromatic indole ring and because HOCl is known to cause tryptophan oxidation (91), W ^{661} is the likely site of oxidation.

Tryptophan residues W ^{460} and W ^{120} were also oxidized in HOCl-treated iPLA $_2\beta$. The former lies near the serine lipase consensus sequence $^{463}\text{GTSTG}^{467}$, and its oxidation thus might affect catalytic activity. Figure 4 is the tandem spectrum of the tryptic peptide $^{456}\text{DLFD}(\text{WO})\text{VAGTSTGGILAILHSK}^{477}$ that contains the oxidized W ^{460} residue. The 202 unit difference in m/z values between fragments y^{18} (m/z 1708.65) and y^{19} (m/z 1910.76) is 16 units greater than the residue mass of W (186 Da). The strong fragmentation at m/z 1892.78 is generated from y^{19} (m/z 1910) by loss of H $_2$ O. Because of the proximity of W ^{460} to the iPLA $_2\beta$ active site, its oxidation could play a role in that component of iPLA $_2\beta$ inactivation by HOCl that cannot be reversed by DTT, and this possibility is examined further below with site-directed mutagenesis studies.

Methionine Oxidation

Of the 26 methionine residues in the iPLA $_2\beta$ sequence, 11 were oxidized by HOCl (Figure 2). Only one methionine residue (M ^{401}) was oxidized by H $_2$ O $_2$, and no other amino acid residues were found to incorporate oxygen in H $_2$ O $_2$ -treated iPLA $_2\beta$. This is consistent with the facts that HOCl reacts readily and rather indiscriminately with thiols and thioethers (63,91) while H $_2$ O $_2$ tends to selectively modify residues in a protein environment that causes them to be especially reactive (52,55,63). No stable amino acid adducts that had incorporated oxygen were identified in NO-treated iPLA $_2\beta$.

DTT Completely Restores Catalytic Activity to HOCl-Treated iPLA $_2\beta$ Mutant Proteins in Which W ^{460} Is Replaced with T ^{460} or Y ^{460} but Not to HOCl-Treated Native iPLA $_2\beta$

To evaluate the possibility that W ^{460} oxidation might play a role in iPLA $_2\beta$ inactivation by HOCl, that residue was replaced with T ^{460} or Y ^{460} by site-directed mutagenesis. His-tagged native iPLA $_2\beta$ and the mutant proteins iPLA $_2\beta$ T ^{460} and iPLA $_2\beta$ Y ^{460} were expressed in a baculovirus-Sf9 cell system and purified by IMAC, and their catalytic activities were then

compared before and after HOCl treatment. Both iPLA₂ β mutant proteins retained essentially full catalytic activity and were nearly completely inactivated by 200 μ M HOCl, as was wild-type iPLA₂ β (Figure 5). Subsequent incubation of the HOCl-treated proteins with DTT restored 97 and 95% of the lost activity of the iPLA₂ β T⁴⁶⁰ and iPLA₂ β Y⁴⁶⁰ mutant proteins, respectively, but DTT restored only 72% of the lost activity of native iPLA₂ β . Mutagenesis of W⁴⁶⁰ to either T or Y thus had little effect per se on iPLA₂ β activity but nearly eliminated the component of iPLA₂ β inactivation by HOCl that cannot be reversed by DTT. W⁴⁶⁰ oxidation thus could be involved in irreversible iPLA₂ β inactivation.

Evidence for Formation of Intermolecular Disulfide Bonds upon Treatment of iPLA₂ β with Biological Oxidants

Immunoblotting analyses indicate that treating iPLA₂ β with H₂O₂, NO, or HOCl causes the enzyme to form higher-molecular mass species that could reflect formation of intermolecular disulfide bonds (Figure 6). Treatment with HOCl resulted in the most dramatic reduction in intensity of the monomeric 85 kDa iPLA₂ β -immunoreactive band (Figure 6A, lane 2), and HOCl also caused a greater reduction in iPLA₂ β thiol content at a given oxidant concentration than did H₂O₂ or NO (Figure 1). All oxidant-treated samples exhibited a broad region of poorly resolved higher-molecular mass iPLA₂ β -immunoreactive species on SDS-PAGE (Figure 6).

For H₂O₂-treated iPLA₂ β samples, incubation with DTT before SDS-PAGE analysis caused the disappearance of the higher-molecular mass species, and only a single 85 kDa iPLA₂ β -immunoreactive band was observed (Figure 6A, lane 5). This is consistent with the fact that incubation with DTT completely restored the free thiol content and activity of H₂O₂-treated iPLA₂ β (Figure 1) and suggests that H₂O₂ induces intermolecular disulfide bond formation between iPLA₂ β monomers.

Biological Oxidant-Induced iPLA₂ β Oligomerization by Mechanisms Other Than Intermolecular Disulfide Bond Formation

In contrast, incubating HOCl-treated iPLA₂ β with DTT did not cause the complete disappearance of the higher-molecular mass immunoreactive species, but their intensity was reduced while that of the 85 kDa monomer increased (Figure 6A, lane 3). In addition, a single, sharp higher-molecular mass band of ~200 kDa was observed after HOCl-treated iPLA₂ β was incubated with DTT rather than the broad region of poorly resolved bands observed before incubation with DTT. Similarly, incubating NO-treated iPLA₂ β with DTT caused a reduction in both the intensity and the heterogeneity of the higher-molecular mass iPLA₂ β -immunoreactive bands and the appearance of a sharply focused 85 kDa band (Figure 6A, lane 7).

The DTT-resistant higher-molecular mass iPLA₂ β -immunoreactive bands produced by treatment with HOCl or with NO might represent oligomers stabilized by strong, noncovalent interactions. Treating apomyoglobin with HOCl causes the appearance of such oligomers, and they can be disrupted by charge repulsion when positively charged amino acids are converted to anions by treatment with succinic anhydride (93). Upon incubation of HOCl-treated iPLA₂ β with succinic anhydride, the DTT-resistant 200 kDa iPLA₂ β -immunoreactive band (Figure 6A,B, lane 3) did disappear (Figure 6B, lane 5), and this band could thus represent an oligomer formed by noncovalent interactions. In contrast, incubating NO-treated iPLA₂ β with succinic anhydride did not cause the complete disappearance of the DTT-resistant higher-molecular mass iPLA₂ β -immunoreactive bands, but it did reduce their heterogeneity and that of the 85 kDa monomer (Figure 6B, lane 9). NO must, therefore, induce oligomerization of iPLA₂ β by mechanisms in addition to forming intermolecular disulfide bonds and noncovalent complexes.

Time- and Temperature-Dependent Inactivation of iPLA₂ β and Thiol Oxidation

Upon storage at 4 °C for 2 weeks, the specific activity of recombinant, purified His-tagged iPLA₂ β fell to ~20% of initial values (not shown). Treating iPLA₂ β samples at that point with DTT resulted in a concentration- and time-dependent increase in activity (Figure 7A,B), although such an effect was not observed with freshly prepared iPLA₂ β (not shown). These findings suggest that reversible thiol oxidation contributes to the loss of activity upon storage of iPLA₂ β .

Consistent with that possibility, immunoblotting analyses of iPLA₂ β that had been freshly prepared (Figure 7C) or stored for 2 weeks at 4 °C (Figure 7D) revealed that storage was associated with the appearance of higher-molecular mass iPLA₂ β -immunoreactive bands that were not observed in fresh iPLA₂ β preparations. These higher-molecular mass bands disappeared upon incubation with DTT (Figure 7D), suggesting that they represented iPLA₂ β oligomers formed by intermolecular disulfide bonds. Because incubation with DTT also increased the activity of stored iPLA₂ β preparations (Figure 7A,B), these observations suggest that intermolecular disulfide bond formation contributes to the loss of activity.

iPLA₂ β undergoes thermal inactivation upon incubation at 37 °C that is largely prevented by including ATP in the incubation medium (94,95). We found that DTT exerts an effect similar to that of ATP to attenuate thermal inactivation of iPLA₂ β (Figure 8A) and that incubating iPLA₂ β at 37 °C also results in the loss of free thiols that is prevented by ATP (Figure 8B). Incubating iPLA₂ β at 37 °C also resulted in the appearance of higher-molecular mass iPLA₂ β -immunoreactive bands on SDS-PAGE that disappeared upon treatment with DTT, and the appearance of these bands was prevented by including ATP in the incubation medium (not shown). This suggests that thermal inactivation of iPLA₂ β is associated with thiol oxidation that is prevented by ATP. There are ATP binding sites in the iPLA₂ β sequence (24,96), and binding might affect the conformation of iPLA₂ β in a way that protects critical thiol groups from oxidation.

The data in Figure 8 also suggest that thiol oxidation is not the sole mechanism contributing to iPLA₂ β thermal inactivation and that ATP protects against inactivation by mechanisms in addition to preventing thiol oxidation. Approximately 80% of iPLA₂ β activity is lost after incubation at 37 °C for 2 h (Figure 8A), but only 30% of the free thiol content is lost. ATP confers complete protection against thiol loss (Figure 8B) but incomplete protection against loss of activity. This could indicate that the loss of certain critical thiols has a larger effect on activity than the loss of others and/or that activity is also lost by mechanisms independent of thiol loss. Approximately 20% of initial activity is lost even in the presence of ATP. Similarly, DTT provides partial but incomplete protection against thermal inactivation (Figure 8A) but presumably complete protection against thiol loss. (The presence of DTT in the incubation medium prevents direct measurement of iPLA₂ β free thiol content.) Approximately 40% of the initial activity is lost in the presence of DTT. These data thus suggest that, of the activity lost after incubation of iPLA₂ β at 37 °C for 2 h, ~50% is attributable to thiol oxidation that is prevented by DTT (or ATP) and ~25% occurs by some other mechanism that is prevented by ATP. Another 25% of the activity loss occurs by a mechanism(s) that is unaffected by ATP.

Identification of iPLA₂ β Disulfide Bonds by LC-MS/MS

Treatment of freshly prepared iPLA₂ β with DTT resulted in decreased heterogeneity of the 85 kDa iPLA₂ β monomer band (Figure 7C), suggesting that heterogeneity might arise from varied degrees of intramolecular disulfide bonding within the population of iPLA₂ β monomers. To examine this possibility, the heterogeneous 85 kDa monomer band of freshly prepared iPLA₂ β analyzed by SDS-PAGE was excised and digested in gel with trypsin. The digest was then analyzed by LC-MS/MS, and ~700 MS/MS spectra so acquired were analyzed by a

modified Signature Discovery program (84) that facilitates identification of disulfide-linked peptides.

The internal disulfide-linked peptide $^{140}\text{IIS}(\text{C-S-})\text{ANSTENEEG}(\text{C-S-})\text{TPLHLACR}^{161}$ was so identified. It contains Cys143, Cys153, and Cys160. The observed m/z value for the precursor ion of the digest peptide representing $^{140}\text{I-R}^{161}$ is 786.96. Therefore, the calculated molecular mass of the parent peptide is 2358 Da. This is 2 Da less than the theoretical mass of 2360 Da for the tryptic peptide $^{140}\text{I-R}^{161}$ from the native sequence, and this suggests that two of the three Cys residues are linked by a disulfide bond. Figure 9A is the deconvoluted MS/MS spectrum obtained from CAD of the $[\text{M} + 3\text{H}]^{3+}$ ion at m/z 786.96. The N-terminal sequence ISS and the C-terminal sequence TPLHLACR are identified by matching theoretical fragment ions with intense peaks in the spectrum. The sequence between Cys143 and Cys153 is not represented by fragment ions because the disulfide bond between these two residues suppresses fragmentation. The difference in m/z values between the singly charged y^8 and y^{19} ions in the spectrum is 1135.32, which is 2 units less than the theoretical mass of the internal fragment $^{143}\text{CANGTENEEGC}^{153}$ (1137.37 Da). The intense ion at m/z 1067 corresponds to the internal fragment $^{144}\text{ANGTENEEGC}^{153}$ or $^{143}\text{CANGTENEEG}^{152}$ (theoretical mass of 1035.4 Da) with an additional sulfur (32 Da) atom derived from the disulfide bond. Figure 8B is the MS/MS spectrum of peptide $^{140}\text{IIS}(\text{C-S-})\text{ANSTENEEG}(\text{C-S-})\text{TPLHLACR}^{161}$ after reduction with DTT and carboxyamidomethylation with iodoacetamide.

Another disulfide-linked peptide was identified from the iPLA $_2\beta$ C-terminal region. The deconvoluted MS/MS spectrum (Figure 10) obtained from CAD of the $[\text{M} + 2\text{H}]^{2+}$ ion at m/z 654.76 from the iPLA $_2\beta$ tryptic digest reveals an internal disulfide bond between Cys679 and Cys680. The mass of the identified peptide ($^{675}\text{MVVDCCTDPDGR}^{686}$) (Figure 10A) is 1307 Da, which is 2 Da less than the theoretical value of 1309 Da for tryptic peptide $^{675}\text{M-R}^{686}$ from the native iPLA $_2\beta$ sequence. All of the expected y -series ions are observed in the MS/MS spectrum except for the y^7 ion, which arises from cleavage of the disulfide bond between the two cysteines. The difference in m/z values between y^6 (m/z 660.27) and y^8 (m/z 864.29) is 204 units, which is also 2 units less than the expected difference of 206 units if there were no disulfide bonds in the intervening sequence. After reduction and carboxyamidomethylation, the mass of the parent peptide $^{675}\text{MVVDCCTDPDGR}^{686}$ increased to 1424 Da, and its MS/MS spectrum contains a strong y^7 ion at m/z 820.28 (Figure 10B). The observed mass is consistent with modification of the two Cys residues in this peptide by carboxyamidomethylation, resulting in a 114 Da increase in mass.

Effects of Oxidative Stress in INS-1 Insulinoma Cells on iPLA $_2\beta$ Oligomerization State, Subcellular Distribution, and Activity

Diamide is a cell-permeant, thiol-specific oxidant that induces mild, noninjurious oxidative stress and disulfide bond formation in intact cells (89,97). INS-1 insulinoma cells that overexpress EGFP-tagged iPLA $_2\beta$ (87) were incubated with diamide and then studied by cytofluorescence microscopy or lysed for iPLA $_2\beta$ immunoblotting and activity assays. Treating the cells with diamide induced the appearance of a high-molecular mass iPLA $_2\beta$ -immunoreactive band upon SDS-PAGE analyses (Figure 11A). This was associated with accumulation of EGFP-iPLA $_2\beta$ into a punctate pattern within the cells on cytofluorescence analyses (Figure 11B) reminiscent of that induced by treating INS-1 cells with thapsigargin to deplete ER Ca $^{2+}$ stores or with cAMP-elevating agents (33,87). Incubating the cells with diamide also caused a decline in iPLA $_2\beta$ activity (Figure 11C) and a concentration-dependent decrease in the rate of release of [^3H]arachidonic acid into the incubation medium (Figure 11D) from cells whose phospholipids had been prelabeled with [^3H]arachidonic acid.

DISCUSSION

The recent demonstration that the widely used iPLA₂ β inhibitor BEL inactivates the enzyme by alkylating critical Cys thiols (50) raises the possibility that thiol modification by biological redox reactions might affect the activity or other properties of the enzyme. Such reactions play important regulatory roles in a variety of biological phenomena (51-54). Because many cells that express iPLA₂ β produce biological oxidants that can modify thiols, it is likely that the enzyme is exposed to such molecules in vivo. iPLA₂ β is expressed in phagocytes, for example, and is a required participant in transcriptional events involved in increasing phagocyte expression of inducible NO synthase (iNOS) in response to viral infection (37). Phagocytes thus can produce NO via iNOS, and they also produce O₂⁻ via NADPH oxidase, which dismutates to H₂O₂ that is used by the phagocyte enzyme MPO to generate HOCl (60-63).

Phagocyte-derived HOCl is also thought to affect proliferation and other properties of vascular wall cells (68,77), and iPLA₂ β is expressed in such cells and participates in regulating their proliferation (43,80). Similarly, iPLA₂ β is expressed in insulin-secreting β -cells (13), which produce both NO via iNOS (78,79) and O₂⁻/H₂O₂ through mitochondrial metabolism and other pathways (73-77). We have also found that β -cells express MPO (S. Bao and J. Turk, unpublished observations), as do neurons (70), and iPLA₂ β is the major PLA₂ in brain neurons (81,82). It is thus likely that iPLA₂ β is exposed to H₂O₂, NO, and HOCl in various cellular contexts, and these biological oxidants could affect the function of the enzyme. Characterizing such effects could be important because factors that regulate iPLA₂ β activity and subcellular distribution are much less well understood than those that affect the better-studied enzyme cPLA₂ α (3,6).

Our observations indicate that biological concentrations of H₂O₂ inactivate iPLA₂ β , and this can be completely reversed by subsequent incubation with DTT. This suggests that inactivation results from covalent modifications that can be reduced by DTT, such as formation of disulfide bonds or sulfenic acids (52,55). Inactivation of iPLA₂ β by NO or HOCl also can be partially reversed by DTT, and this presumably reflects similar covalent modifications of the enzyme. NO- or HOCl-induced iPLA₂ β inactivation also has a component that cannot be reversed by DTT, and this presumably reflects DTT-resistant covalent modifications, such as formation of sulfonic acids, Trp oxides, Met sulfoxides, or others (52,55).

DTT-reversible covalent modifications were observed upon LC-MS/MS analyses of tryptic digests of oxidant-treated iPLA₂ β . Cys332 and Cys651, for example, were converted to sulfenic acid derivatives upon oxidant treatment, and Cys559 was further oxidized to the stable sulfonic acid derivative. In previous studies, Cys was the only amino acid residue observed to be modified during the inactivation of iPLA₂ β and its covalent modification by the suicide substrate BEL, and modification of Cys651 correlated most closely with BEL-induced inactivation of iPLA₂ β (50). Moreover, site-directed mutagenesis of Cys651 to Ala yielded an active mutant enzyme with reduced sensitivity to inhibition (50). It is thus possible that oxidation of Cys651 to a sulfenic acid might be a mechanism for regulating iPLA₂ β activity that would be reversible by subsequent reduction to the free thiol.

Formation of cysteine sulfenic acid (Cys-SOH) residues in iPLA₂ β upon treatment with biological oxidants is of interest because protein-sulfenic acids are now recognized to play important roles in redox regulation (51-55,98). Cys-SOH formation causes reversible inhibition of protein tyrosine phosphatases (99,100) and glutathione reductase (101) during tyrosine phosphorylation-dependent signal transduction events and nitrosative stress, respectively. Cys-SOH also participates in the redox regulation of transcription factors such as Fos, c-Jun/Activator protein-1 and bovine papillomavirus-1 E2 protein (102-104).

A second class of DTT-reversible covalent modifications of oxidant-treated iPLA₂ β that was identified is disulfide bond formation. Intramolecular disulfide bonds (Cys143-S-S-Cys153 and Cys679-S-S-Cys680) were also identified in fresh iPLA₂ β preparations even under conditions where free thiol groups were blocked, suggesting that these bonds were not generated during processing and may exist in the enzyme within cells. Incubating freshly prepared iPLA₂ β with DTT reduced these bonds but caused little change ($\leq 20\%$ increase) in activity, suggesting that the bonds may not be critical in regulating catalytic activity, although they could have a role in governing the interaction of the enzyme with other proteins (86) or its subcellular distribution (87).

Intermolecular disulfide bond formation appears to be involved in the spontaneous time- and temperature-dependent oxidation of iPLA₂ β that occurs without exposure to added biological oxidants, and this is also associated with the loss of enzymatic activity. That intermolecular disulfide bond formation could affect properties of iPLA₂ β in vivo is suggested by the facts that subjecting INS-1 insulinoma cells to mild oxidative stress with diamide induced formation of iPLA₂ β -immunoreactive oligomers that could be reduced by DTT and that this was associated with the loss of iPLA₂ β activity in cell lysates, the subcellular redistribution of EGFP-tagged iPLA₂ β on cytofluorescence analyses, and a reduction in the rate of release of [³H]arachidonic acid from membrane phospholipids.

Although spontaneous, time- and temperature-dependent oxidative inactivation of iPLA₂ β has a component that can be reversed by incubation with DTT, there is another component that is not. Binding of ATP appears to reduce both modes of inactivation, possibly by causing the enzyme to adopt a conformation that renders it less susceptible to oxidation. Such a conformational change might be involved in the effect of ATP to prevent completely the time- and temperature-dependent loss of free thiol groups in iPLA₂ β , and protection against thiol oxidation might account for the long recognized but previously unexplained effect of ATP in attenuating iPLA₂ β thermal inactivation (94,95). There is also a component of time- and temperature-dependent iPLA₂ β inactivation that is not prevented by ATP or reversed by DTT.

Covalent modifications that cannot be reversed by DTT that were observed upon LC-MS/MS analyses of tryptic digests of oxidant-treated iPLA₂ β included formation of sulfonic acids, Trp oxides, and Met sulfoxides. Although Trp and Met oxidation can occur during sample processing, such oxidations can also serve regulatory functions in vivo. Oxidation of a specific Trp residue (W⁶⁰) in B-crystallin has been demonstrated (105), and oxidation of a critical conserved Trp residue (W³⁵²) in luminal loop E of chloroplast photosystem II protein CP43 is a highly selective in vivo modification (106). Oxidation of a methionine residue (M¹¹⁰) to the sulfoxide in cathepsin G targets the enzyme for proteolysis (107). The oxidized residue W⁴⁶⁰ identified here in oxidant-treated iPLA₂ β is located near the serine lipase consensus sequence (⁴⁶³GTSTG⁴⁶⁷), and its oxidation could represent one mechanism for irreversible iPLA₂ β inactivation. That possibility is consistent with our finding that mutagenesis of W⁴⁶⁰ to less readily oxidizable residues yields active mutant enzymes that no longer exhibit a DTT-irreversible component of HOCl-induced inactivation.

In summary, two distinct modes of iPLA₂ β inactivation occur upon exposure to biological oxidants (Figure 12). One can be reversed by DTT and is associated with formation of higher-molecular mass oligomers that can be reduced by DTT. DTT-reversible oxidation events could include formation of Cys-sulfenic acid derivatives and/or of Cys-Cys disulfide bonds, and both were observed in oxidant-treated iPLA₂ β . Formation of Cys651-sulfenic acid could represent one mechanism for DTT-reversible iPLA₂ β inactivation because alkylation of that residue by the suicide substrate BEL is strongly associated with loss of activity, and mutagenesis to a nonalkylatable residue reduces the sensitivity to inhibition (50). Another mode of oxidative iPLA₂ β inactivation cannot be reversed with DTT and could be caused by Trp or Met oxidation

or by formation of Cys-sulfonic acid derivatives, and all of these modifications were also observed in oxidant-treated iPLA₂β. W⁴⁶⁰ oxidation could represent one mechanism for irreversible iPLA₂β inactivation because of the proximity of that residue to the ⁴⁶³GTSTG⁴⁶⁷ catalytic center and because its mutagenesis to a less readily oxidizable residue protects against irreversible inactivation. Although the relevance of these studies to biological function within cells remains unproven as yet, the findings described above and the observation that subjecting insulinoma cells to mild oxidative stress affects iPLA₂β oligomerization state, activity, and subcellular distribution and alters release of arachidonic acid from phospholipids suggest that iPLA₂β might be subject to intracellular redox regulation.

ACKNOWLEDGMENT

We thank Dr. Mary Wohltmann, Alan Bohrer, Wu Jin, and Sheng Zhang for excellent technical assistance and Jessica Jackson for secretarial assistance.

REFERENCES

1. Brash AR. Arachidonic acid as a bioactive molecule. *J. Clin. Invest* 2001;107:1339–45. [PubMed: 11390413]
2. Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. *Proc. Natl. Acad. Sci. U.S.A* 2004;101:245–50. [PubMed: 14681556]
3. Six D, Dennis E. The expanding superfamily of phospholipase A₂ enzymes: Classification and characterization. *Biochim. Biophys. Acta* 2000;1488:1–19. [PubMed: 11080672]
4. Ma Z, Turk J. The molecular biology of the Group VIA Ca²⁺-independent phospholipase A₂. *Prog. Nucleic Acid Res. Mol. Biol* 2001;67:1–33. [PubMed: 11525380]
5. Murphy RC, Fitzpatrick FA. Arachidonate related lipid mediators. *Methods Enzymol* 1990;187:1–628.
6. Gijon M, Spencer D, Kaiser A, Leslie C. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A₂. *J. Cell Biol* 1999;145:1219–32. [PubMed: 10366595]
7. Underwood KW, Song C, Kriz RW, Chang XJ, Knopf JL, Lin LL. A novel calcium-independent phospholipase A₂, cPLA₂γ, that is prenylated and contains homology to cPLA₂. *J. Biol. Chem* 2002;273:21926–32. [PubMed: 9705332]
8. Pinckard RT, Striffler BA, Kramer RM, Sharp JD. Molecular cloning of two new human paralogs of 85 kDa cytosolic phospholipase A₂. *J. Biol. Chem* 1999;274:8823–31. [PubMed: 10085124]
9. Song C, Chang XJ, Bean KM, Proia MS, Knopf JL, Kriz RW. Molecular characterization of cytosolic phospholipase A₂β. *J. Biol. Chem* 1999;274:17063–7. [PubMed: 10358058]
10. Ohto T, Uozumi N, Hirabayashi T, Shimizu T. Identification of novel cytosolic phospholipase A₂s, murine cPLA₂δ, ε, and ζ, which form a gene cluster with cPLA₂β. *J. Biol. Chem* 2005;280:24576–83. [PubMed: 15866882]
11. Tang J, Kriz RW, Wolfman N, Shaffer M, Seehra J, Jones SS. A novel cytosolic calcium-independent phospholipase A₂ contains eight ankyrin motifs. *J. Biol. Chem* 1997;272:8567–75. [PubMed: 9079687]
12. Balboa MA, Balsinde J, Jones S, Dennis EA. Identity between the calcium-independent phospholipase A₂ enzymes from P388D1 macrophages and Chinese hamster ovary cells. *J. Biol. Chem* 1997;272:8576–90. [PubMed: 9079688]
13. Ma Z, Ramanadham S, Kempe K, Chi XS, Ladenson J, Turk J. Pancreatic islets express a Ca²⁺-independent phospholipase A₂ enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. *J. Biol. Chem* 1997;272:11118–27. [PubMed: 9111008]
14. Balsinde J, Dennis EA. Function and inhibition of intracellular calcium-independent phospholipase A₂. *J. Biol. Chem* 1997;272:16069–72. [PubMed: 9195897]
15. Hazen SL, Zupan LA, Weiss RH, Getman DP, Gross RW. Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A₂. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A₂. *J. Biol. Chem* 1991;266:7227–32. [PubMed: 2016324]

16. Zupan LA, Weiss RH, Hazen S, Parnas BL, Aston KW, Lennon PJ, Getman DP, Gross RW. Structural determinants of haloenol lactone-mediated suicide inhibition of canine myocardial calcium-independent phospholipase A₂. *J. Med. Chem* 1993;36:95–100. [PubMed: 8421294]
17. Ma Z, Ramanadham S, Hu Z, Turk J. Cloning and expression of a type IV cytosolic phospholipase A₂ enzyme from a pancreatic islet cDNA library. Comparison of the expressed activity with that of the islet type VI cytosolic phospholipase A₂. *Biochim. Biophys. Acta* 1998;1391:384–400. [PubMed: 9555100]
18. Balsinde J, Dennis EA. Distinct roles in signal transduction for each of the phospholipase A₂ enzymes present in P388D1 macrophages. *J. Biol. Chem* 1996;271:6758–65. [PubMed: 8636097]
19. Mancuso D, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A₂. *J. Biol. Chem* 2000;275:9937–45. [PubMed: 10744668]
20. Tanaka H, Takeya R, Sumimoto H. A novel intracellular membrane-bound calcium-independent phospholipase A₂. *Biochem. Biophys. Res. Commun* 2000;272:320–6. [PubMed: 10833412]
21. Yang J, Han X, Gross RW. Identification of hepatic peroxisomal phospholipase A₂ and characterization of arachidonic acid-containing choline glycerophospholipids in hepatic peroxisomes. *FEBS Lett* 2003;546:247–50. [PubMed: 12832049]
22. Mancuso DJ, Jenkins CM, Sims HF, Cohen JM, Yang J, Gross RW. Complex transcriptional and translational regulation of iPLA₂γ resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization. *Eur. J. Biochem* 2004;271:4709–24. [PubMed: 15606758]
23. Van TM, Atkins J, Li Y, Glynn P. Human neuropathy target esterase catalyzes hydrolysis of membrane lipids. *J. Biol. Chem* 2002;277:20942–8. [PubMed: 11927584]
24. Jenkins CM, Mancuso DJ, Yan W, Sims HF, Gibson B, Gross RW. Identification, cloning, expression, and purifications of three novel human calcium-independent phospholipase A₂ family members possessing triacylglycerol lipase and acylglycerol transacylase activities. *J. Biol. Chem* 2004;279:48968–75. [PubMed: 15364929]
25. Balsinde J, Bianco ID, Ackerman EJ, Conde-Friebos K, Dennis EA. Inhibition of calcium-independent phospholipase A₂ prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc. Natl. Acad. Sci. U.S.A* 1995;92:8527–31. [PubMed: 7667324]
26. Baburina I, Jackowski S. Cellular responses to excess phospholipid. *J. Biol. Chem* 1999;274:9400–8. [PubMed: 10092620]
27. Larsson PKA, Claesson HE, Kennedy BP. Multiple splice variants of the human calcium-independent phospholipase A₂ and their effect on enzyme activity. *J. Biol. Chem* 1998;273:207–14. [PubMed: 9417066]
28. Ma Z, Wang X, Nowatzke W, Ramanadham S, Turk J. Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A₂ (iPLA₂) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA₂ gene on chromosome 22q13.1. *J. Biol. Chem* 1999;274:9607–16. [PubMed: 10092647]
29. Balboa MA, Saez Y, Balsinde J. Calcium-independent phospholipase A₂ is required for lysozyme secretion in U937 promonocytes. *J. Immunol* 2003;170:5276–80. [PubMed: 12734377]
30. Owada S, Larsson O, Arkhammar P, Katz AI, Chibalin AV, Berggren PO, Bertorello AM. Glucose decreases Na⁺,K⁺-ATPase activity in pancreatic β-cells. An effect mediated via Ca²⁺-independent phospholipase A₂ and protein kinase C-dependent phosphorylation of the α-subunit. *J. Biol. Chem* 1999;274:2000–8. [PubMed: 9890957]
31. Ramanadham S, Song H, Hsu FF, Zhang S, Crankshaw M, Grant G, Newgard C, Turk J. Pancreatic islets and insulinoma cells express a novel isoform of Group VIA phospholipase A₂ (iPLA₂β) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA₂β transcript. *Biochemistry* 2003;42:13929–40. [PubMed: 14636061]
32. Atsumi GI, Murakami M, Kojima K, Hadano A, Tajima M, Kudo I. Distinct roles of two intracellular phospholipase A₂s in fatty acid release in the cell death pathway. Proteolytic fragment of type IVA cytosolic phospholipase A₂α inhibits stimulus-induced arachidonate release, whereas that of type VI Ca²⁺-independent phospholipase A₂ augments spontaneous fatty acid release. *J. Biol. Chem* 2000;275:18248–58. [PubMed: 10747887]

33. Ramanadham S, Hsu FF, Zhang S, Jin C, Bohrer A, Ma Z, Turk J. Involvement of the Group VIA Phospholipase A₂ (iPLA₂ β) in endoplasmic reticulum stress-induced apoptosis in insulinoma cells. *Biochemistry* 2004;43:918–30. [PubMed: 14744135]
34. Jenkins CM, Han X, Mancuso DJ, Gross RW. Identification of calcium-independent phospholipase A₂ β (iPLA₂ β), and not iPLA₂ γ as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA₂s. *J. Biol. Chem* 2002;277:32807–14. [PubMed: 12089145]
35. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, Bolotina VM. A novel mechanism for the store-operated calcium influx pathway. *Nat. Cell Biol* 2004;6:113–20. [PubMed: 14730314]
36. Williams SD, Ford DA. Calcium-independent phospholipase A₂ mediates CREB phosphorylation and c-fos expression during ischemia. *Am. J. Physiol* 2001;281:H168–76.
37. Moran JM, Butler RM, McHowat J, Turk J, Wohltmann M, Gross RW, Corbett JA. Genetic and pharmacologic evidence that iPLA₂ β regulates virus-induced iNOS expression by macrophages. *J. Biol. Chem* 2005;280:28162–8. [PubMed: 15946940]
38. Murakami M, Kambe T, Shimbara S, Kudo I. Functional coupling between various phospholipase A₂s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. *J. Biol. Chem* 1999;274:3103–15. [PubMed: 9915849]
39. Tay HR, Melendez AJ. Fc γ RI-triggered generation of arachidonic acid and eicosanoids requires iPLA₂ but not cPLA₂ in human monocytic cells. *J. Biol. Chem* 2004;279:22505–13. [PubMed: 15007079]
40. Ma Z, Bohrer A, Wohltmann M, Ramanadham S, Hsu F-F, Turk J. Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress Group VIA phospholipase A₂. *Lipids* 2001;36:689–700. [PubMed: 11521967]
41. Bao S, Bohrer A, Ramanadham S, Jin W, Zhang S, Turk J. Effects of stable suppression of Group VIA phospholipase A₂ expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. *J. Biol. Chem* 2006;281:187–98. [PubMed: 16286468]
42. Manguikian AD, Barbour SE. Cell cycle dependence of group VIA calcium-independent phospholipase A₂ activity. *J. Biol. Chem* 2004;279:52881–92. [PubMed: 15385540]
43. Yellaturu CR, Rao GN. A requirement for calcium-independent phospholipase A₂ in thrombin-induced arachidonic acid release and growth in vascular smooth muscle cells. *J. Biol. Chem* 2003;278:43831–7. [PubMed: 12928445]
44. Roshak AK, Capper EA, Stevenson C, Eichman C, Marshall LA. Human calcium-independent phospholipase A₂ mediates lymphocyte proliferation. *J. Biol. Chem* 2000;275:35692–8. [PubMed: 10964913]
45. Ramanadham S, Ma Z, Arita H, Zhang S, Turk J. Type IB secretory phospholipase A₂ is contained in the insulin secretory granules of pancreatic islet β cells and is co-secreted with insulin upon stimulation of islets with glucose. *Biochim. Biophys. Acta* 1998;1390:301–12. [PubMed: 9487151]
46. Balsinde J, Dennis EA. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. *J. Biol. Chem* 1996;271:31937–41. [PubMed: 8943239]
47. Fuentes L, Perez R, Nieto ML, Balsinde J, Balboa MA. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A₂. *J. Biol. Chem* 2003;278:44683–90. [PubMed: 12952946]
48. Daniels SB, Cooner E, Sofia MJ, Chakravarty PK, Katzenellenbogen JA. Haloenol lactones. Potent enzyme-activated irreversible inhibitors for α -chymotrypsin. *J. Biol. Chem* 1983;258:15046–53. [PubMed: 6654902]
49. Daniels SB, Katzenellenbogen JA. Halo enol lactones: Studies on the mechanism of inactivation of α -chymotrypsin. *Biochemistry* 1986;25:1436–44. [PubMed: 3964685]
50. Song H, Ramanadham S, Bao S, Hsu F-F, Turk J. A bromoenol lactone suicide substrate inactivates Group VIA phospholipase A₂ by generating a diffusible bromomethyl ketoacid that alkylates cysteine thiols. *Biochemistry* 2006;45:1061–73. [PubMed: 16411783]
51. Paget MSV, Buttner MJ. Thiol-based regulatory switches. *Annu. Rev. Genet* 2003;37:91–121. [PubMed: 14616057]

52. Poole LB, Karplus OA, Claiborne A. Protein sulfenic acids in redox signaling. *Annu. Rev. Pharmacol. Toxicol* 2004;44:325–47. [PubMed: 14744249]
53. Soberman RJ. The expanding network of redox signaling: New observations, complexities, and perspectives. *J. Clin. Invest* 2003;111:571–4. [PubMed: 12618508]
54. Voss AA, Lango J, Ernst-Russell M, Morin D, Pessah IN. Identification of hyperreactive cysteines within ryanodine receptor type I by mass spectrometry. *J. Biol. Chem* 2004;279:34514–20. [PubMed: 15197184]
55. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. *Curr. Opin. Cell Biol* 2005;17:183–9. [PubMed: 15780595]
56. Georgiu G, Masip L. An overoxidation journey with a return ticket. *Science* 2003;300:592–4. [PubMed: 12714731]
57. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. *Science* 2003;300:650–3. [PubMed: 12714747]
58. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, Rhee SG. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. *Science* 2003;300:653–6. [PubMed: 12714748]
59. Nathan C. Specificity of a third kind: Reactive oxygen and nitrogen intermediates in cell signaling. *J. Clin. Invest* 2003;111:769–78. [PubMed: 12639979]
60. Palazzolo AM, Suquet C, Konkelt ME, Hurst JK. Green fluorescent protein-expressing *Escherichia coli* as a selective probe for HOCl generation within neutrophils. *Biochemistry* 2005;44:6910–9. [PubMed: 15865436]
61. Chapman ALP, Hampton MB, Senthilmohan B, Winterbourn CC, Kettle AJ. Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of *Staphylococcus aureus*. *J. Biol. Chem* 2002;277:9757–62. [PubMed: 11733505]
62. King DA, Hannum DM, Qi JS, Hurst JK. HOCl-mediated cell death and metabolic dysfunction in the yeast *Saccharomyces cerevisiae*. *Arch. Biochem. Biophys* 2004;423:170–81. [PubMed: 14871479]
63. Schraufstatter IU, Browne K, Harris A, Hyslop PA, Jackson JH, Quehenberger O, Cochrane CG. Mechanisms of hypochlorite injury of target cells. *J. Clin. Invest* 1990;85:554–62. [PubMed: 2153710]
64. Vissers MCM, Winterbourn CC. Oxidation of intracellular glutathione after exposure of human red blood cells to hypochlorous acid. *Biochem. J* 1995;307:57–62. [PubMed: 7717994]
65. Pullar JM, Winterbourn CC, Vissers MCM. Loss of GSH and thiol enzymes in endothelial cells exposed to sublethal concentrations of hypochlorous acid. *Am. J. Physiol* 1999;277:H1505–12. [PubMed: 10516189]
66. Pullar JM, Vissers MCM, Winterbourn CC. Glutathione oxidation by hypochlorous acid in endothelial cells produces glutathione sulfonamide as a major product but not glutathione disulfide. *J. Biol. Chem* 2001;276:22120–5. [PubMed: 11283008]
67. Vile GF, Rothwell LA, Kettle AJ. Hypochlorous acid activates the tumor suppressor protein p53 in cultured human skin fibroblasts. *Arch. Biochem. Biophys* 1998;359:51–6. [PubMed: 9799559]
68. Vissers MCM, Pullar JM, Hampton MB. Hypochlorous acid causes caspase activation and apoptosis or growth arrest in human endothelial cells. *Biochem. J* 1999;344:443–9. [PubMed: 10567227]
69. Midwinter RG, Vissers MCM, Winterbourn CC. Hypochlorous acid stimulation of the mitogen-activated protein kinase pathway enhances cell survival. *Arch. Biochem. Biophys* 2001;394:13–20. [PubMed: 11566022]
70. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, Heinecke JW. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. *J. Neurochem* 2004;90:724–33. [PubMed: 15255951]
71. Atouf F, Czernichow P, Scharfmann R. Expression of neuronal traits in pancreatic β cells. Implication of neuron-restrictive silencing factor repressor element silencing transcription factor, a neuron-restrictive silencer. *J. Biol. Chem* 1997;272:1929–34. [PubMed: 8999882]
72. Hsu F-F, Bohrer A, Turk J. Electrospray ionization tandem mass spectrometric analysis of sulfatide. Determination of fragmentation patterns and characterization of sulfatide molecular species

- expressed in brain and pancreatic islets. *Biochim. Biophys. Acta* 1998;1392:202–16. [PubMed: 9630631]
73. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β cells in diabetes. *J. Biol. Chem* 2004;279:42351–4. [PubMed: 15258147]
  74. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. *Diabetes* 2005;54:1615–25. [PubMed: 15919781]
  75. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Masumura T, Araki E. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. *Diabetes* 2006;55:120–7. [PubMed: 16380484]
  76. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. *Diabetes* 2006;55:225–33. [PubMed: 16380497]
  77. Fortuno A, San Jose G, Moreno MU, Belouqui O, Diez J, Zalba G. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. *Diabetes* 2006;56:209–15. [PubMed: 16380495]
  78. Ma Z, Ramanadham S, Corbett J, Bohrer A, Gross RW, McDaniel ML, Turk J. Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism. *J. Biol. Chem* 1996;271:1029–42. [PubMed: 8557627]
  79. Ma Z, Landt M, Bohrer A, Ramanadham S, Kipnis DM, Turk J. Interleukin-1 reduces the glycolytic utilization of glucose by pancreatic islets and reduces glucokinase mRNA content and protein synthesis by a nitric oxide-dependent mechanism. *J. Biol. Chem* 1997;272:17827–35. [PubMed: 9211938]
  80. Meyer MC, Kell PJ, Creer MH, McHowat J. Calcium-independent phospholipase A₂ is regulated by a novel protein kinase C in human coronary artery endothelial cells. *Am. J. Physiol* 2005;288:C475–80.
  81. Yang HC, Mosior M, Ni B, Dennis EA. Regional distribution, ontogeny, purification, and characterization of the Ca²⁺-independent phospholipase A₂ from rat brain. *J. Neurochem* 1999;73:1278–87. [PubMed: 10461922]
  82. Balboa MA, Varela-Nieto I, Killermann L, Lucas K, Dennis EA. Expression and function of phospholipase A₂ in brain. *FEBS Lett* 2002;531:12–7. [PubMed: 12401195]
  83. Or HK, Fisher MT, Schoneich C. Potential role of methionine sulfoxide in the inactivation of eth chaperone GroEL by hypochlorous acid and peroxynitrite. *J. Biol. Chem* 2004;279:19486–93. [PubMed: 14757771]
  84. Song H, Hecimovic S, Goate A, Hsu FF, Bao S, Vidavsky I, Ramanadham S, Turk J. Characterization of N-terminal processing of group VIA phospholipase A₂ and of potential cleavage sites of amyloid precursor protein constructs by automated identification of signature peptides in LC/MS/MS analyses of proteolytic digests. *J. Am. Soc. Mass Spectrom* 2004;12:1780–93. [PubMed: 15589755]
  85. Gross RW, Ramanadham S, Kruszka KK, Han X, Turk J. Rat and human pancreatic islet cells contain a calcium ion independent phospholipase A₂ activity selective for hydrolysis of arachidonate, which is stimulated by adenosine triphosphate and is specifically localized to islet β -cells. *Biochemistry* 1993;32:327–36. [PubMed: 8418853]
  86. Wang Z, Ramanadham S, Ma Z, Bao S, Mancuso DJ, Gross RW, Turk J. Group VIA phospholipase A₂(iPLA₂ β) forms a signaling complex with the calcium/calmodulin-dependent protein kinase II β expressed in pancreatic islet β -cells. *J. Biol. Chem* 2005;280:6840–9. [PubMed: 15576376]
  87. Bao S, Jin C, Zhang S, Turk J, Ma Z, Ramanadham S. Tracking iPLA₂ β movements in response to stimulation with insulin secretagogues in INS-1 cells. *Diabetes* 2004;53:S186–9. [PubMed: 14749286]
  88. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: Oxidants, myeloperoxidase, and bacterial killing. *Blood* 1998;92:3007–17. [PubMed: 9787133]
  89. Brennan JP, Wait R, Begum S, Bell JR, Dunn MJ, Eaton P. Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. *J. Biol. Chem* 2004;279:41352–60. [PubMed: 15292244]

90. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. *J. Clin. Invest* 2003;111:583–93. [PubMed: 12618510]
91. Winterbourn CC, Kettle AJ. Biomarkers of myeloperoxidase-derived hypochlorous acid. *Free Radical Biol. Med* 2000;29:403–9. [PubMed: 11020661]
92. Raftery MJ, Yang Z, Valenzuela SM, Geczy CL. Novel intra- and inter-molecular sulfinamide bonds in S100A8 produced by hypochlorite oxidation. *J. Biol. Chem* 2001;36:33393–401. [PubMed: 11445563]
93. Chapman AL, Winterbourn CC, Brennan SO, Jordan TW, Kettle AJ. Characterization of non-covalent oligomers of proteins treated with hypochlorous acid. *Biochem. J* 2003;1375:33–40. [PubMed: 12852783]
94. Ramanadham S, Wolf MJ, Jett PA, Gross RW, Turk J. Characterization of an ATP-stimulatable Ca^{2+} -independent phospholipase A_2 from clonal insulin-secreting HIT cells and rat pancreatic islets: A possible molecular component of the β -cell fuel sensor. *Biochemistry* 1994;33:7442–52. [PubMed: 8003509]
95. Balsinde J, Dennis EA. Function and inhibition of intracellular calcium-independent phospholipase A_2 . *J. Biol. Chem* 1997;272:16069–72. [PubMed: 9195897]
96. Wolf MJ, Gross RW. Expression, purification, and kinetic characterization of a recombinant 80-kDa intracellular calcium-independent phospholipase A_2 . *J. Biol. Chem* 1996;271:30879–85. [PubMed: 8940072]
97. Cumming RC, Andon NL, Haynes PA, Park M, Fischer WH, Schubert D. Protein disulfide bond formation in the cytoplasm during oxidative stress. *J. Biol. Chem* 2004;279:21749–58. [PubMed: 15031298]
98. Claiborne A, Yeh JI, Mallett TC, Luba J, Crane EJ III, Charrier V, Parsonage D. Protein-sulfenic acids: Diverse roles for an unlikely player in enzyme catalysis and redox regulation. *Biochemistry* 1999;38:15407–16. [PubMed: 10569923]
99. Denu JM, Tanner KG. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: Evidence for a sulphenic acid intermediate and implications for redox regulation. *Biochemistry* 1998;37:5633–42. [PubMed: 9548949]
100. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. *Mol. Cell* 2002;9:387–99. [PubMed: 11864611]
101. Claiborne A, Mallett TC, Yeh JI, Luba J, Parsonage D. Structural, redox, and mechanistic parameters for cysteine-sulfenic acid function in catalysis and regulation. *Adv. Protein Chem* 2001;58:215–76. [PubMed: 11665489]
102. Xanthoudakis S, Miao GG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. *Proc. Natl. Acad. Sci. U.S.A* 1994;91:23–7. [PubMed: 7506414]
103. Gorman MA, Morera S, Rothwell DG, de La Fortelle E, Mol CD, Tainer JA, Hickson ID, Freemont PS. The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites. *EMBO J* 1997;16:6548–58. [PubMed: 9351835]
104. Rothwell DG, Barzilay G, Gorman M, Morera S, Freemont P, Hickson ID. The structure and functions of the HAP1/Ref-1 protein. *Oncol. Res* 1997;9:275–80. [PubMed: 9406232]
105. MacCoss MJ, McDonald WH, Saraf A, Sadygov R, Clark JM, Tasto JJ, Gould KL, Wolters D, Washburn M, Weiss A, Clark JI, Yates JR III. Shotgun identification of protein modifications from protein complexes and lens tissue. *Proc. Natl. Acad. Sci. U.S.A* 2002;99:7900–5. [PubMed: 12060738]
106. Anderson LB, Maderia M, Ouellette AJ, Putnam-Evans C, Higgins L, Krick T, MacCoss MJ, Lim H, Yates JR III, Barry BA. Posttranslational modifications in the CP43 subunit of photosystem II. *Proc. Natl. Acad. Sci. U.S.A* 2002;99:14676–81. [PubMed: 12417747]
107. Shao B, Belaouaj A, Verlinde CL, Fu X, Heinecke JW. Methionine sulfoxide and proteolytic cleavage contribute to the inactivation of cathepsin G by hypochlorous acid: An oxidative mechanism for regulation of serine proteinases by myeloperoxidase. *J. Biol. Chem* 2005;280:29311–21. [PubMed: 15967795]

Figure 1.

Effects of biological oxidants and dithiothreitol on the catalytic activity and thiol content of recombinant, purified group VIA phospholipase A₂ (iPLA₂β). Varied concentrations of H₂O₂ (A), the NO donor compound diethylamine NONQate (B), or HOCl (C) were added to solutions of recombinant, His-tagged iPLA₂β (0.2 μg/mL) that had been purified by IMAC, and the mixtures were incubated at 37 °C for 30 min. The oxidation reactions were then quenched with a 10-fold molar excess of L-methionine. Aliquots of each sample were then removed for measurement of iPLA₂β activity (■) and free thiol content (▲). A third aliquot of each sample was incubated with 2.5 mM DTT at 37 °C for 30 min, and iPLA₂β activity was then measured (◆). Displayed values represent means ± SD (n = 6).

1	(MO) QFFGRLVNT	LSSVTNLFSN	PFRVKEVSLA	DYASSERVRE	EGQLILLQNA	SNRTWDCVLV
61	SPRNPQSGFR	<u>LFQLESEADA</u>	<u>LVNFQQYSSQ</u>	<u>LPPFYESSVQ</u>	<u>VLHVEVLQHL</u>	<u>TDLIRNHPS (WO)</u>
121	TVTHLAVELG	IREFHHSRI	ISCANSTENE	EGCTPLHLAC	<u>RKGDSEILVE</u>	<u>LVQYCHAQMD</u>
181	<u>VTDNKGETAF</u>	<u>HYAVQGDNPQ</u>	<u>VLQLLGKNAS</u>	AGLNQVNNQG	LTPLHLACQ (MO)	GKQEMVRVLL
241	LCNARCNI (MO) G	PGGFPIHTA (MO)	KFSQKGCAE (MO)	IIS (MO) DSNQIH	<u>SKDPRYGASF</u>	<u>LHWAKNAEMA</u>
301	<u>RMLLKRGCDV</u>	DSTSASGNTA	LHAVVTRNRF	D (CO) V (MO) VLLTYG	ANAGARGEHG	NTPLHLA (MO) SK
361	<u>DNMEMVKALI</u>	VFGAEVDTPN	DFGETPAFIA	<u>SKISKQLQDL</u>	(MO) PVSRAKPA	FILSS (MO) RDEK
421	RSHDHLLCLD	GGGVKGLVII	<u>QLLIAIEKAS</u>	<u>GVATKDLFD (WO)</u>	VAGTSTGGIL	ALAILHSKSM
481	AYMRGVYFRM	KDEVFRGSRP	YESGPLEEFL	<u>KREFGEHTKM</u>	<u>TDVKKPKVML</u>	TGTLSDRQPA
541	ELHLFRNYDA	PEAVREPR (CO ₃) T	PNINLKPTQ	<u>PADQLVWRAA</u>	<u>RSSGAAPTIF</u>	RPNGRFLDGG
601	LLANNPTLDA	(MO) TEIHEYNQD	(MO) <u>IRKGQGNKV</u>	<u>KKLSIVVSLG</u>	TGKSPQVPVT	(CO) VDVFRPSNP
661	(WO) <u>ELAKTVFGA</u>	<u>KELGKMVVD</u>	<u>CTDPDGRAVD</u>	<u>RARAWCEMVG</u>	<u>IQYFRLNPQL</u>	GSDIMLDEVS
721	DAVLVNALWE	<u>TEVYIYEHRE</u>	<u>EFQKLVQLLL</u>	SP		

Figure 2.

Sequence coverage obtained in LC–MS/MS analyses of tryptic digests of oxidant-treated iPLA₂ β and identified sites of oxidative modification. Only the underlined regions of sequence were not identified in LC–MS/MS analyses of tryptic digests of HOCl-treated iPLA₂ β . MO and WO denote methionine and tryptophan oxidation, respectively. CO denotes sulfenic acid, and CO₃ denotes sulfonic acid.

Figure 3.

Deconvoluted tandem mass spectrum expressed as singly charged ions obtained from collisionally activated dissociation (CAD) of the $[M + 3H]^{3+}$ ion of the oxidized peptide $^{644}\text{SPQVPVT}(\text{CO})\text{VDVFRPSNP}(\text{WO})\text{ELAK}^{665}$ in a tryptic digest of oxidant-treated iPLA $_2\beta$. An aliquot (10 μg) of freshly prepared, recombinant, purified iPLA $_2\beta$ was incubated at 37 °C for 30 min with HOCl at a molar ratio of 1:50. The reaction was quenched with a 10-fold molar excess of L-methionine, and digestion with trypsin was performed. The digest was analyzed by LC-MS/MS, and the displayed spectrum of singly charged ions was obtained by CAD of the $[M + 3H]^{3+}$ precursor ion at m/z 834.39 and deconvolution of the charge states.

Figure 4. Deconvoluted tandem mass spectrum obtained from CAD of the $[M + 3H]^{3+}$ ion (m/z 801.09) of the oxidized peptide $^{455}\text{DLFD(WO)VAGTSTGGILALAILHSK}^{477}$ in a tryptic digest of oxidant-treated iPLA $_2\beta$.

Figure 5.

Effect of site-directed mutagenesis of iPLA₂ β residue W⁴⁶⁰ to T or Y on the catalytic activity and susceptibility to irreversible biological oxidant-induced inactivation. The His-tagged mutant proteins iPLA₂ β T⁴⁶⁰ and iPLA₂ β Y⁴⁶⁰ were produced by site-directed mutagenesis, expressed in a baculovirus–Sf9 cell system, and purified by IMAC. Catalytic activities of native iPLA₂ β and the mutant proteins were then determined before and after treatment with HOCl and then with DTT, as described in the legend of Figure 1. Displayed values represent the loss of activity in the treated samples compared to the control activity of untreated samples and are expressed as means $\pm$ SD ($n = 6$).

Figure 6.

Immunoblotting analyses of iPLA₂β preparations treated with biological oxidants, dithiothreitol, and succinic anhydride. Aliquots (2 μg) of freshly prepared, purified, recombinant, His-tagged iPLA₂β (panels A and B, lane 1) were treated with 200 μM HOCl (panel A, lanes 2–4, and panel B, lanes 2–6), H₂O₂ (panel A, lanes 4–6), or the NO donor diethylamine NONQate (panel A, lanes 6 and 7, and panel B, lanes 6–9). The indicated samples (panel A, lanes 3, 5, and 7, and panel B, lanes 3, 5, 7, and 9) were then incubated with 2.5 mM DTT at 37 °C for 30 min. In panel B (lanes 4, 5, 8, and 9), the indicated samples were treated with 4.5 μg/μL succinic anhydride. SDS–PAGE analyses were then performed under nonreducing conditions, and immunoblotting was performed with iPLA₂β antibodies after the transfer to PVDF membranes.

Figure 7.

Effects of dithiothreitol on time-dependent changes in the iPLA₂β catalytic activity and oligomerization state that occur during storage. Samples (50 pmol) of recombinant, purified, His-tagged iPLA₂β that had been stored at 4 °C for 2 weeks were incubated with 2 mM DTT at room temperature for various (0–150 min) intervals (A) or with varied concentrations (0–50 mM) of DTT for 60 min (B), and iPLA₂β activity was then measured. Displayed values represent means ± SD (*n* = 6). Aliquots (2 μg) of iPLA₂β that had been freshly prepared (C) or stored at 4 °C for 2 weeks (D) were also analyzed by nonreducing SDS–PAGE and immunoblotting before (left-most lanes of panels C and D) or after (right-most lanes of panels C and D) incubation with 2.5 mM DTT at 37 °C for 30 min. Immunoblots were probed with antibodies to iPLA₂β.

Figure 8.

Effects of dithiothreitol and ATP on the thermal inactivation and thiol content of iPLA₂ β . Freshly prepared, recombinant, purified, His-tagged iPLA₂ β was incubated with vehicle only ($\blacktriangle$), with 2.5 mM DTT ($\blacksquare$), or with 10 mM ATP ($\blacklozenge$) at 37 °C for various (0–120 min) intervals, and aliquots were removed for measurement of enzymatic activity (A) and thiol content (B). Displayed values represent means $\pm$ SD ($n = 6$).

Figure 9.

Demonstration of an intramolecular disulfide bond between Cys143 and Cys153 in the iPLA $_2\beta$ tryptic peptide ^{140} IISCANSTENEEGCTPLHLACR ^{161} by tandem MS. Panel A is the deconvoluted MS/MS spectrum obtained from CAD of the $[M + 3H]^{3+}$ precursor ion at m/z 786.96 and demonstrates that the parent peptide contains a disulfide bond between Cys143 and Cys153. Panel B is the analogous MS/MS spectrum obtained from CAD of the $[M + 3H]^{3+}$ precursor ion at m/z 844.68 after reduction and carboxyamidomethylation of the parent peptide.

Figure 10.

Demonstration of an intramolecular disulfide bond between Cys679 and Cys680 in the iPLA₂ β tryptic peptide ⁶⁷⁵MVVDCTDPDGR⁶⁸⁶ by tandem MS. Panel A is the deconvoluted MS/MS spectrum obtained from CAD of the $[M + 2H]^{2+}$ precursor ion at m/z 654.72 and demonstrates that the parent peptide contains a disulfide bond between Cys679 and Cys680. Panel B is the analogous MS/MS spectrum obtained from CAD of the $[M + 2H]^{2+}$ precursor ion at m/z 712.73 after reduction and carboxyamidomethylation of the parent peptide.

Figure 11.

Effects of oxidative stress caused by treating INS-1 insulinoma cells with the cell-permeant thiol oxidant diamide on iPLA₂β oligomerization state, subcellular distribution, and catalytic activity. INS-1 insulinoma cells that express EGFP-tagged iPLA₂β were incubated (37 °C for 10 min) with diamide (5 mM). Aliquots of cell suspensions were removed before (A, lane 1) and after (A, lanes 2 and 3) incubation with diamide and then treated (A, lane 3) or not treated (A, lanes 1 and 2) with 2.5 mM DTT and analyzed by SDS-PAGE under nonreducing conditions. Immunoblotting was then performed with iPLA₂β antibody after transfer to PVDF membranes (A). In panel B, fluorescence microscopic analyses were performed with INS-1 cells infected with an empty viral vector (top micrographs) or with a viral vector containing cDNA encoding EGFP-tagged iPLA₂β (bottom micrographs) and incubated without (left micrographs) or with (right micrographs) diamide (5 mM). In panel C, iPLA₂β catalytic activity was determined in aliquots of lysates from INS-1 cells that had been incubated without (left bar) or with (right bar) diamide (5 mM). In panel D, INS-1 cells were preincubated with [³H] arachidonic acid to label their phospholipids and then washed to remove unincorporated radiolabel. Aliquots of cell suspensions were then seeded onto 16-well plates and incubated (30 min at 37 °C under 95% air and 5% CO₂) with the indicated concentrations of diamide. Aliquots of media were then removed for determination of the amount of released [³H] arachidonic acid by liquid scintillation spectrometry. Displayed values represent means ± SD (*n* = 6). Asterisks indicate *p* < 0.05 vs the control condition.

Figure 12.

Reversible and irreversible oxidative covalent modifications of iPLA₂ β and modes of catalytic inactivation. Treatment of iPLA₂ β with biological oxidants reduces catalytic activity, and this is partially but incompletely reversed by dithiothreitol, indicating that there are reversible and irreversible modes of oxidative inactivation. Some covalent modifications induced by oxidants, e.g., formation of Cys-sulfenic acids or disulfide bonds, can also be reversed upon incubation with DTT, while others, e.g., Trp oxidation or formation of Met sulfoxide or Cys sulfonic acids, are not reversible.